Becton, Dickinson and Company · NYSE:BDX
Becton, Dickinson and — Technical Presentation (April 2020)
28 slides from Becton, Dickinson and's technical presentation, April 2020
Slide 1: Presenter views disclaimer
These presentations were developed by the respective presenter(s), and the findings, interpretations, and conclusions contained or expressed with them do not necessarily reflect the views of BD. To the extent these presentations relate to specific products, such products should always be used in acc
Slide 2: MACOVA2020 Multidisciplinary Advanced Course on Vascular Access
rr er eee @eee ~eee% See oe e ee MACOVA2020 Multidisciplinary Advanced Course on Vascular Access a ey
Slide 3: Appropriate choice of device in the oncology patient
The appropriate choice of device in the oncology patient: review of the literature and survey 2019 Prof. Baudolino Mussa
Slide 4: The present… open our minds..
The present… open our minds..
Slide 5: US central venous access devices market forecast
Technavio's analysts forecast the central venous access devices market in the US to grow at a CAGR of 7.85% over the period 2015-2019. Market Driver • Increasing Aging Population Market Challenge • High Risk of Vein Thrombosis Market Trend • Growing Incidence of CABSI
Slide 6: The PICC explosion..
The picc explosion.. Technavio’s market research analysts estimate the global PICC market to grow at a CAGR of around6.5% between 2015 and 2019. The global market for peripherally inserted central catheter (PICC) is heavily influenced by factors like the rising incidence of chronic diseas patients t
Slide 7: Global Central Venous Access Devices Market 2014-2018
Global Central Venous Access Devices Market 2014-2018 Published: January 2014 TechNavio's analysts forecast the Global Central Venous Access Devices market to grow at a CAGR of 4.10 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing aging p
Slide 8: Bloodstream Infection, Venous Thrombosis, and PICCs: Reappraising the Evidence
THE AMERICAN JOURNAL of MEDICINEs Bloodstream Infection, Venous Thrombosis, and Peripherally Inserted Central Catheters: Reappraising the Evidence ‘Vineet Chopra, MD, MSc,> Sarah Anand, MD,? Sarah L. Krein, RN, PhD,** Carol Chenoweth, MD,‘ ‘Sanjay Saint, MD, MPH** “Division of General Internal Medic
Slide 9: Bloodstream Infection, Venous Thrombosis, and PICCs
Bloodstream Infection, Venous Thrombosis, and Peripherally Inserted Central Catheters: Reappraising the Evidence ‘Vineet Chopra, MD, MSc,? Sarah Anand, MD, Sarah L. Krein, RN, PhD,** Carol Chenoweth, MD,< ‘Sanjay Saint, MD, MPH** “Division of General Interaal Medicine, "Hospital Outcomes Program of
Slide 10: Bloodstream Infection, Venous Thrombosis, and PICCs
THE AMERICAN MEDICINE® Bloodstream Infection, Venous Thrombosis, and Peripherally Inserted Central Catheters: Reappraising the Evidence ‘Vineet Chopra, MD, MSc,> Sarah Anand, MD,? Sarah L. Krein, RN, PhD,** Carol Chenoweth, MD,‘ ‘Sanjay Saint, MD, MPH** “Division of General Internal Medicine, *Hospi
Slide 11: Complication rate PICC versus other VAD
Complication rate PICC versus other VAD (Cotogni Mussa 2013)
Slide 12: Vad out hospital complication rate
Vad out hospital complication rate (Cotogni Mussa 2013)
Slide 13: Outcome CVC outside hospital VAD
Outcome CVC outside hospital VAD (Cotogni Mussa 2013)
Slide 14: The right CVC for the right patients
The right CVC at the beginning. The right CVC for the right patients The longest life for device….
Slide 15: Our idea: dedicated CVC Team
Our idea: dedicated CVC Team Every nurse or doctor with approved training course can ask to partecipate Check of eligibility of formation received Enrollment in Cvc Team Albo When the number of requested picc for member is more than 400 we insert a new member with: • 50 picc placement tutored • Prac
Slide 16: Complicanze Trombotiche, Settiche e Meccaniche
Complicanze Trombotiche, Settiche e Meccaniche Frequenza infusioni 7/7 <7/7 Non noto dei pazienti in NPD-IICB Risulta ti Caratteristiche dei cateteri Frequenza deitipi dicvc 140 Sito di posizionamento 41% - Giugulare int.Dx/&i - 31% 20% a2 - Gucclavia Dx/ - 17% 9% - Nondocumentato - 5% 100 > 27% 3 2
Slide 17: Complicanze Trombotiche, Settiche e Meccaniche
Complicanze Trombotiche, Settiche e Meccaniche dei pazienti in NPD-IICB Risulta ti Caratteristiche dei cateteri Parze Tot. Imp 1540 giorni (r 875-1989) 0b 1 i 1 1 L i 0 1000 2000 3000 4000 5000 6000 Time
Slide 18: Complicanze Trombotiche, Settiche e Meccaniche dei pazienti in NPD-IICB
Complicanze Trombotiche, Settiche e Meccaniche dei pazienti in NPD-IICB Risultati: Complicanze TOT IMP 1 (4%) 4 (16%) 1 (4%) PARZ IMP 83 2 (2.4%) 11 (13%) 11 (13%) HOHN 126 1 (0.8%) 9 (7%) 22 (17.4%) PICC 64 4 (6%) 3 (5%) 20 (31%) TOTALE 298 7 (2.3%) 27 (9%) 53 (18%) TOT IMP 16 0 (0%) 2 (12.5%) 0 (0
Slide 19: Early ecographic study in oncological patients with picc
Early ecographic study in oncological patients with picc
Slide 20: Early ecographic study in oncological patients with picc
Early ecographic study in oncological patients with picc
Slide 21: Internal data analysis
INTERNAL DATA ANALYSIS • 200 patients involved Complete data recording (vein size, time for procedure, complications, etc) • Weekly echografic check for trombosis for 4 weeks then monthly RESULTS murali intraluminali Total thrombosis: 26 (17% of 150 patients), 15 vein occludenti obstruction, 7 on ve
Slide 22: Timing of PICC thrombosis
TIMING OF PICC THROMBOSIS 18 14 riscontro trombosi 9 5 0 I sett II sett III sett > IV sett
Slide 23: Risk of Adverse Events Related to Extended-Dwell Peripheral IV Access
INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY CONCISE COMMUNICATION The Risk of Adverse Events Related to Extended-Dwell Peripheral Intravenous Access Sara Campagna, PhD, RN;' Silvia Gonella, RN, MSc; Pietro Antonio Zerla, RN;* Gianvito Corona, MD;* Tiziana Correggia, RN, MSc;* Baudolino Mussa, MD;” Pao
Slide 24: Table 2. Individual Adverse Events
TABLE 2. Individual Adverse Events (n= 154) No. of Time Elapsed Between Complications — MC Positioning and per 1,000 Onset of AE, median d Adverse Events No. MC days (IQR; range) Occlusion* 89 1.44 13 (6-28; 1-273) Symptomatic 37 0.92 19 (8-32; 1-307) thrombosis” Exit-site infection’ 8 0.13 9 (7,.8-
Slide 25: Evidence Based Medicine: PICCs in Patients with Cancer Receiving Chemotherapy
EVIDENCE BASED MEDICINE Publsied Ahead of Pinon Fetruary Ontologist 2019 8 10.1634Heonco}oN. 2018-0281 ‘Symptom Management and Supportive Care Can Peripherally Inserted Central Catheters Be Safely Placed in Patients with Cancer Receiving Chemotherapy? A Retrospective Study of Almost 400,000 Catheter
Slide 26: Evidence Based Medicine
EVIDENCE BASED MEDICINE Results. Among the 2,477 included patients, 419 PICC- related AEs (16.9%; 1,09 AEs per 1,000 PICC-days) were reported. AEs increased when PICC was inserted at the bra- chial site (hazard ratio [HR], 1.37; 95% confidence interval [Cl], 1.02-1.84) and with open systems (HR, 1.8
Slide 27: Retrospective study of safety of PICC days for parenteral treatments
EVIDENCE BASED MEDICINE astanen anricie wey BY A retrospective study of the safety of over 100,000 peripherally-inserted central catheters days for parenteral supportive treatments Sara Campagna PhO, RN! | Silvia Gonella RN, MSc, PhO student*© | Paola Berchialla PAD | Carla Rigo RN* | Giacomo Morano
Slide 28: Thank you
THANK YOU baudolino.mussa@unito.it
Becton, Dickinson and Company — Technical Presentation (April 2020) on 6ix